17

Sep, 2020

Central and Eastern European Meeting on Viral Hepatitis and HIV

Tags:

The Central and Eastern European Meeting on Viral Hepatitis and HIV is an independent program, initiated in 2014 and developed by regional and international key opinion leaders for the medical and scientific community in Eastern and Central European countries. The target audience of this meeting consists of healthcare professionals involved in daily care for HCV patients such as infectious disease doctors, gastroenterologists, hepatologists and others. The sixth edition of the Central and Eastern European Meeting on Viral Hepatitis and HIV will be held as a virtual conference. To apply for virtual participation scholarships click here. Click here for […]

READ MORE

9

Sep, 2020

Actual problems of HIV Infection: Mother and Child

Tags: ,

Penta has been invited to run a one-day session at the Republican Hospital of Infectious Diseases, St Petersburg conference on ‘Actual problems of HIV Infection: Mother and Child’ on Tuesday 15th September. The Penta session What’s new for children and women living with HIV: interactive clinical day with Penta will look at new data on ART in pregnancy and newborns, resistance and recommendations for 1st, 2nd and further lines, supporting our adolescents and coinfections. Register to conference!

READ MORE

7

Sep, 2020

The effect of pregnancy on the pharmacokinetics of total and unbound Dolutegravir and its main metabolite in women living with Human Immunodeficiency Virus

Tags:

Authors: Bollen P, Freriksen J, Konopnicki D, Weizsäcker K , et al; on behalf of the Pharmacokinetics of ANtiretroviral agents in HIV-infected pregNAnt women Network Published in: Clin infect Dis. 2020;26.ciaa006 Background Pharmacokinetic and efficacy data on dolutegravir in pregnant women living with human immunodeficiency virus (HIV) are still limited but needed to support its use as one of the preferred antiretroviral agents. Methods Within the multicenter Pharmacokinetics of ANtiretroviral agents in HIV-infected pregNAnt women (PANNA) study, pregnant women living with HIV and using dolutegravir once daily (50 mg, with food) […]

READ MORE

21

Jul, 2020

The CARMA study: early infant antiretroviral therapy—Timing impacts on total HIV-1 DNA quantitation 12 years later

Tags: ,

Authors: Foster C, Domínguez-Rodríguez S, Tagarro A, et al. For the Early Treated Perinatally HIV Infected Individuals: Improving Children’s Actual Life (EPIICAL) Consortium Published in: J Pediatr Infect Dis Soc. 2020 2020 Jul 17;piaa071 Background Strategies aimed at antiretroviral therapy (ART)–free remission will target individuals with a limited viral reser- voir. We investigated factors associated with low reservoir measured as total human immunodeficiency virus type 1 (HIV-1) DNA in peripheral blood mononuclear cells (PBMCs) in perinatal infection (PaHIV). Methods Children from 7 European centers in the Early Treated Perinatally HIV […]

READ MORE
NEWSLETTER

We would like to update you on our recent activities